Atyr PHARMA INC (NASDAQ:ATYR) Receives $19.25 Average Price Target from Analysts

Shares of Atyr PHARMA INC (NASDAQ:ATYR) have earned a consensus rating of “Buy” from the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $18.60.

Several equities analysts recently commented on the stock. Leerink Partnrs upgraded shares of Atyr PHARMA to a “strong-buy” rating in a research note on Tuesday, February 18th. Leerink Partners began coverage on Atyr PHARMA in a report on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Atyr PHARMA in a research note on Tuesday, December 10th. Finally, Cantor Fitzgerald assumed coverage on Atyr PHARMA in a report on Monday, January 6th. They issued an “overweight” rating on the stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. boosted its stake in Atyr PHARMA by 52.0% in the third quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock valued at $55,000 after acquiring an additional 10,754 shares during the last quarter. Alterna Wealth Management Inc. bought a new position in shares of Atyr PHARMA in the fourth quarter worth approximately $36,000. Kingswood Wealth Advisors LLC bought a new stake in shares of Atyr PHARMA during the 4th quarter worth $170,000. American Century Companies Inc. bought a new position in shares of Atyr PHARMA during the 4th quarter valued at about $319,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Atyr PHARMA in the 4th quarter worth approximately $39,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Atyr PHARMA Price Performance

NASDAQ:ATYR opened at $4.32 on Tuesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.41 and a quick ratio of 5.41. The firm’s fifty day moving average price is $3.64 and its two-hundred day moving average price is $2.89. Atyr PHARMA has a one year low of $1.42 and a one year high of $4.66. The company has a market cap of $362.62 million, a P/E ratio of -4.60 and a beta of 1.10.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.